The research team, led by Xuesong Xu and Shichong Qiao, began with a large-scale data trawl rather than a single hypothesis. They mined a publicly available bulk RNA-sequencing dataset from a rabbit model of post-traumatic temporomandibular joint osteoarthritis, using the limma statistical framework to identify genes whose activity shifted between healthy and diseased tissue. The screen was deliberately broad: genes with an absolute log2 fold change above 0.5 and a nominal p-value below 0.05 were flagged as differentially expressed, then fed into pathway enrichment analyses, gene set enrichment analysis and protein interaction network construction through the STRING database and Cytoscape. The results painted a coherent picture of a joint under siege.

Among the thousands of altered genes, a clear pattern emerged. Inflammatory mediators such as IL6, CXCL9, CXCL10 and STAT1 were ramped up, as were the catabolic enzymes MMP13 and ADAMTS5, which chew through cartilage matrix. Meanwhile, the structural genes that keep cartilage intact, including ACAN and COL2A1, were suppressed, and so was a cluster of genes tied to autophagy and oxidative stress control that orbit the transcription factor FOXO3. Pathway analysis confirmed the shift: TNF, NF-kB and chemokine signalling were positively enriched in osteoarthritic tissue, while FoxO signalling, autophagy and extracellular matrix organisation were negatively enriched. FoxO3, a forkhead box transcription factor known to regulate cell survival, inflammatory cascades and tissue repair, sat squarely at the centre of this storm.

To test whether restoring FoxO3 could protect the joint, the team turned to Sprague-Dawley rats. They delivered an adeno-associated virus vector, AAV5-CAG-rFoxO3-IRES-EGFP, directly into the temporomandibular joints to force FoxO3 expression, then induced osteoarthritis by injecting monosodium iodoacetate, a compound that disrupts chondrocyte metabolism. Eighteen rats were divided into three groups of six: a sham control, an osteoarthritis group receiving an empty vector, and an osteoarthritis group receiving the FoxO3 vector. Four weeks later, the joints were harvested and scrutinised with micro-computed tomography, histological staining and immunofluorescence.

The protective effect of FoxO3 was striking. Micro-CT revealed that the subchondral bone volume fraction was significantly higher in the FoxO3-treated group than in untreated osteoarthritic joints, with a corresponding reduction in trabecular separation, a measure of bone deterioration. Histology told the same story from the soft tissue side: cartilage surfaces were more intact, inflammatory cell infiltration was reduced, proteoglycan content was higher, and OARSI cartilage damage scores dropped significantly. At the molecular level, the catabolic enzymes MMP-13 and ADAMTS-5 were downregulated while the matrix markers Col2a1 and Aggrecan were upregulated, indicating that FoxO3 had shifted chondrocytes from a destructive, inflammatory state back toward matrix production and repair.

In cultured primary rat chondrocytes, the team confirmed the mechanism in finer detail. Overexpressing FoxO3 enhanced the deposition of acidic glycosaminoglycans, visible through Alcian blue staining, boosted Col2a1 protein levels and accelerated cell proliferation in a 24-hour scratch assay. But the central question remained: what controls FoxO3 in the first place? The answer came from small RNA sequencing of diseased and healthy joints, which identified 34 dysregulated microRNAs. Machine learning feature selection, combining LASSO regression and a linear support vector machine, converged on a single candidate: rno-miR-223-3p, which was significantly elevated in osteoarthritic tissue.

MicroRNAs are short regulatory RNAs that silence genes by binding complementary sequences in messenger RNA. Bioinformatic prediction with TargetScan suggested that rno-miR-223-3p could bind not only to the 3-prime untranslated region of FoxO3 mRNA but also to a long non-coding RNA called OIP5-AS1. This is where the study’s regulatory architecture becomes elegant. Long non-coding RNAs longer than 200 nucleotides can act as competing endogenous RNAs, effectively molecular sponges that soak up microRNAs and prevent them from repressing their targets. When the researchers transfected chondrocytes with a miR-223-3p mimic, FoxO3 expression fell at both the mRNA and protein levels; blocking the microRNA with an inhibitor had the opposite effect, restoring FoxO3 and, with it, Col2a1 expression and matrix synthesis.

The emerging model is a three-way regulatory axis. In healthy cartilage, OIP5-AS1 binds and neutralises miR-223-3p, keeping FoxO3 active and chondrocytes resilient. During disease, inflammatory signals such as interleukin-1 beta, which prior work has shown to suppress OIP5-AS1 in a dose- and time-dependent manner through presumed NF-kB pathway activation, reduce the sponge’s capacity. Free miR-223-3p rises, directly represses FoxO3, and the chondrocyte loses its antioxidant defences, its matrix production and its resistance to apoptosis. FoxO3 is known to activate downstream targets such as SOD2 and CAT that buffer oxidative stress, so its loss leaves cells vulnerable to the very inflammatory environment that osteoarthritis creates.

The authors are careful about the limits of their work. The mechanistic experiments relied primarily on cell models, and the OIP5-AS1 arm of the axis has not yet been directly manipulated in living animals; they propose constructing OIP5-AS1 knockdown and overexpression rat models combined with the monosodium iodoacetate challenge as the next step. They also note that FoxO3 activity is modulated by phosphorylation through the PI3K/Akt pathway, and that crosstalk with NF-kB signalling remains unexplored. No clinical samples were analysed, so the expression pattern of the axis in human temporomandibular joint osteoarthritis patients is still unknown. Beyond chondrocytes, miR-223-3p is a recognised regulator of macrophage polarisation and FoxO3 influences osteoblast and osteoclast behaviour, suggesting the axis may also shape synovial inflammation and subchondral bone remodelling across the whole joint.

Even with those caveats, the study delivers a genuinely actionable target. The demonstration that a single viral vector delivering FoxO3 into the joint can preserve bone architecture, cartilage integrity and matrix composition in a rat model of temporomandibular joint osteoarthritis provides proof of concept for gene-based therapy in a condition that currently has no etiological treatment. The OIP5-AS1/miR-223-3p/FoxO3 axis, the authors conclude, holds promise both as a diagnostic biomarker and as a therapeutic lever, offering a molecularly precise strategy for intervening in a disease that has long been managed only with pain relief and, eventually, surgery. For the millions whose jaws grind through daily life, that precision cannot come soon enough.

Subject of Research: The OIP5-AS1/miR-223-3p/FoxO3 regulatory axis in temporomandibular joint osteoarthritis and chondrocyte survival

Article Title: OIP5‐AS1 Sponges miR‐223‐3p to Upregulate FoxO3 and Ameliorate Temporomandibular Joint Osteoarthritis by Inhibiting Chondrocyte Apoptosis

Article References: Xu, X., & Qiao, S. (2026). OIP5 ‐ AS1 Sponges miR ‐223‐3p to Upregulate FoxO3 and Ameliorate Temporomandibular Joint Osteoarthritis by Inhibiting Chondrocyte Apoptosis. Journal of Cellular and Molecular Medicine, 30(17), Article e71359. https://doi.org/10.1111/jcmm.71359

Image Credits: AI Generated

DOI: 10.1111/jcmm.71359

Keywords: temporomandibular joint osteoarthritis, FoxO3, OIP5-AS1, miR-223-3p, chondrocyte apoptosis, long non-coding RNA, cartilage degeneration, gene therapy, micro-CT, extracellular matrix, inflammation, AAV5 vector

Small nucleolar RNAs, or snoRNAs, are best known for their housekeeping roles in the nucleus, where they guide the chemical modification of ribosomal RNA and help assemble the protein-making machinery of the cell. For years they were treated as molecular plumbers, essential but unglamorous. That perception has shifted as sequencing technologies have revealed that snoRNAs are frequently processed into smaller fragments, known as sdRNAs, some of which behave like microRNAs and regulate gene expression by binding to messenger RNAs. The Chinese team began their investigation by performing two independent sdRNA-sequencing analyses, one on cartilage tissue and one on chondrocytes isolated from patients with osteoarthritis, to systematically catalog which of these fragments might be associated with the disease.

That screen flagged sdRNA-D21 as a molecule of interest. Follow-up measurements using quantitative real-time PCR and fluorescence in situ hybridization confirmed that sdRNA-D21 is overexpressed in osteoarthritic cartilage compared with healthier tissue, and, critically, that its abundance correlates clinically with the severity of knee osteoarthritis. In other words, the more advanced the disease, the more of this small RNA was present in the patients’ joint cartilage. Correlation alone does not establish causation, so the researchers moved to functional experiments, employing synthetic mimics to raise sdRNA-D21 levels and antisense inhibitors to suppress them in chondrocyte cultures, a classic gain- and loss-of-function strategy for probing what a molecule actually does.

The results were unambiguous. When the team knocked down sdRNA-D21, chondrocyte survival improved and the cellular damage associated with osteoarthritis was alleviated in laboratory models. Conversely, elevating the fragment promoted the programmed death of chondrocytes, a process known as apoptosis. Because the loss of chondrocytes is a central event in cartilage breakdown, anything that speeds their demise is a plausible contributor to disease progression. To extend the finding beyond the culture dish, the researchers turned to an in vivo model in which osteoarthritis is induced in rats by destabilization of the medial meniscus, a surgical manipulation that mimics joint instability. Silencing sdRNA-D21 in these animals eased the development of osteoarthritic changes, providing evidence that the fragment is not merely a bystander marker of damaged tissue but an active participant in the degenerative process.

The heart of the paper lies in its mechanistic dissection of how sdRNA-D21 exerts its destructive influence, and here the study reveals a two-pronged attack centered on the endoplasmic reticulum, the intracellular network of membranes where newly made proteins are folded and quality-controlled. Chondrocytes living in the harsh biochemical environment of an osteoarthritic joint experience chronic stress in this compartment, a condition called ER stress. Cells normally respond by adjusting their protein folding capacity, but if stress persists and cannot be resolved, the ER can trigger apoptosis. One of the cell’s key defense mechanisms is ER-phagy, a selective form of autophagy in which damaged or stressed segments of the ER are engulfed and degraded, allowing the compartment to recover and restoring balance.

Through a combination of bioinformatic target prediction, luciferase reporter assays, RNA pulldown experiments and RNA immunoprecipitation, the researchers showed that sdRNA-D21 binds to the messenger RNA of BAG2, a protein that ordinarily supports the ER-phagy machinery. By targeting BAG2, sdRNA-D21 prevents the recruitment of p62, an adaptor protein that acts as the physical link between cargo marked for destruction and the autophagic machinery. Without p62 recruitment, ER-phagy falters. The consequence is that stressed ER material accumulates instead of being cleared, tilting the cell toward the apoptotic pathway. The team corroborated these intracellular effects using transmission electron microscopy and fluorescence co-localization, techniques that allow direct visualization of ER architecture and autophagic structures at subcellular resolution.

The second prong of the attack involves a different axis of ER stress regulation. The researchers found that sdRNA-D21 silences the expression of DEPTOR, a naturally occurring inhibitor of the mechanistic target of rapamycin signaling network whose loss has been linked to heightened cellular stress responses. With DEPTOR suppressed, the E3 ubiquitin ligase TRC8 is unleashed to enhance ER stress signaling, amplifying the very stress that the compromised ER-phagy pathway can no longer resolve. Interactions between the relevant proteins were verified by co-immunoprecipitation, rounding out a molecular circuit in which a single small RNA fragment simultaneously removes a pro-survival quality control system and intensifies the stress stimulus that the quality control system is meant to counteract. The dual mechanism helps explain why sdRNA-D21 is such an effective promoter of chondrocyte apoptosis.

What makes this study notable in the broader context of osteoarthritis research is the light it throws on the so-called dark matter of the genome. The human genome is transcribed far more extensively than the set of protein-coding genes alone would suggest, and fragments derived from non-coding RNAs are increasingly implicated in common diseases. Osteoarthritis has been slower than cancer or neurodegeneration to attract this kind of molecular scrutiny, partly because its clinical course is slow and its tissue is difficult to access. By combining patient-derived sequencing data, a comprehensive toolkit of molecular interaction assays, and an animal model, the Guangzhou team has assembled an unusually complete causal chain, from a clinically correlated RNA marker through defined protein targets to cellular pathology and finally to disease outcomes in living animals.

The therapeutic implications are tentative but tangible. Because sdRNA-D21 knockdown alleviated disease in both cell culture and the rat model, antisense-based approaches that neutralize the fragment could in principle protect chondrocytes and slow cartilage degeneration, a goal that current osteoarthritis treatments, which largely manage pain and function, do not achieve. BAG2-mediated ER-phagy and the DEPTOR-TRC8 stress axis likewise offer downstream checkpoints that drug developers might target. Substantial hurdles remain, including delivering RNA-targeted therapeutics into cartilage tissue and confirming the findings across larger patient cohorts, and the published version of the study remains subject to standard editorial finalization. Still, the identification of a snoRNA-derived fragment as a molecular driver of osteoarthritis marks an expansion of the disease’s known biology and provides, as the authors describe it, a foundational basis for the development of targeted intervention strategies against one of the world’s most burdensome chronic conditions.

Subject of Research: Role of the snoRNA-derived fragment sdRNA-D21 in ER stress-induced chondrocyte apoptosis and osteoarthritis progression

Article Title: Novel snoRNA-derived fragment sdRNA-D21 enhances ER stress-induced chondrocyte apoptosis in osteoarthritis by targeting BAG2-mediated ER-phagy and DEPTOR

Article References: Novel snoRNA-derived fragment sdRNA-D21 enhances ER stress-induced chondrocyte apoptosis in osteoarthritis by targeting BAG2-mediated ER-phagy and DEPTOR. (n.d.). https://doi.org/10.1007/s00018-026-06442-4

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06442-4

Keywords: sdRNA-D21, snoRNA, osteoarthritis, chondrocytes, ER stress, ER-phagy, BAG2, DEPTOR, TRC8, apoptosis, non-coding RNA, cartilage degeneration

The connection between telomere biology and osteoarthritis has been building for more than two decades. Articular chondrocytes are largely post-mitotic but retain a limited capacity to divide during tissue maintenance and repair. Each round of cell division erodes the protective telomeric caps at chromosome ends, and when these caps become critically short, cells trigger replicative senescence through the p53-p21 and p16-Rb pathways. Studies of cartilage harvested from osteoarthritic joints have repeatedly shown that chondrocytes near the lesion display shorter telomeres and higher levels of senescence markers, including senescence-associated beta-galactosidase, than cells taken from regions farther from the damage. Senescent chondrocytes secrete a cocktail of matrix-degrading enzymes, inflammatory cytokines, and reactive oxygen species, a phenomenon often described as the senescence-associated secretory phenotype, which propagates tissue damage to neighboring cells and accelerates extracellular matrix breakdown.

Telomerase, the ribonucleoprotein reverse transcriptase composed of the TERT catalytic subunit and the TERC RNA template, is the principal enzyme counteracting this erosion. In most human somatic tissues telomerase is silenced after development, but certain stem cell compartments and specialized cells maintain low-level activity. The strict limitation of telomerase expression reflects an evolutionary trade-off: while telomerase permits extended replicative lifespan, inappropriate reactivation is a near-universal feature of cancer. Any therapeutic strategy that boosts telomerase in a degenerating tissue must therefore contend with the theoretical risk of promoting aberrant cell proliferation or tumorigenesis. This concern makes the discovery of a naturally occurring, locally acting telomerase regulator particularly interesting, because endogenous factors that modulate TERT expression within a defined tissue microenvironment may offer a more physiologically balanced approach than global pharmacological telomerase activation.

The identification of MYDGF in this context was enabled by an unbiased genome-wide CRISPR-Cas9 screening strategy coupled with a TERT reporter system. Such screens allow researchers to systematically perturb every gene in the genome and observe which disruptions raise or lower reporter output, thereby revealing previously unknown regulators of a pathway of interest. That MYDGF emerged as a strong positive regulator of telomerase was unexpected, since the protein had not previously been associated with telomere biology. Follow-up experiments in HeLa cells and in the ATDC5 chondrogenic cell line confirmed that MYDGF positively regulates TERT expression and telomerase enzymatic activity, establishing that the screening result reflected a genuine molecular relationship rather than a screening artifact.

MYDGF itself has an interesting history. First described in the early 2000s under alternative names including stromal cell-derived growth factor and interleukin-25, the protein is a 173-amino-acid secreted factor produced by diverse cell types, including bone marrow-derived macrophages, adipocytes, hepatocellular carcinoma cells, and human synovial cells. Nuclear magnetic resonance structural studies have shown that it adopts a fold built from alpha-helices and beta-sheets, with a predicted receptor-interacting interface that has yet to be fully characterized. Its best-established role came from cardiovascular research, where bone marrow-derived cells were shown to secrete MYDGF after myocardial infarction to promote cardiomyocyte survival and angiogenesis, likely through activation of MAPK and Akt signaling. The PI3K/Akt pathway is itself well known for supporting cartilage health, promoting expression of the matrix components collagen type II and aggrecan while suppressing the catabolic enzyme MMP13, which provides a plausible mechanistic bridge between MYDGF signaling and matrix homeostasis.

Beyond the heart, MYDGF has been implicated in several other disease settings. In diabetic nephropathy, expression of the factor is reduced, and supplementation appears to protect kidney function by modulating autophagy and limiting podocyte apoptosis. MYDGF expression has also been linked to the effectiveness of anti-fibrotic therapy, suggesting a role in restraining organ fibrosis. Because protein drugs often suffer from short circulating half-lives, protein engineering efforts have produced a fusion construct, MYDGF164, that appends a region of human CD164 to MYDGF, markedly prolonging its persistence while retaining biological activity; this engineered protein alleviated renal fibrosis in chronic kidney disease models. Such work demonstrates that MYDGF-based therapeutics are technically feasible and provides a template that could be adapted for joint-directed delivery.

The in vivo evidence in the osteoarthritis study strengthens the case that MYDGF is not merely correlated with cartilage health but functionally involved in it. In the surgically induced destabilization of the medial meniscus model, a widely used mouse paradigm in which joint instability accelerates cartilage wear, mice lacking MYDGF developed more severe cartilage damage than their wild-type counterparts. Conversely, adeno-associated virus-mediated delivery of MYDGF into the knee joint partially protected cartilage from injury. AAV vectors are attractive for intra-articular gene delivery because they can drive sustained local expression of a therapeutic gene within the joint with a relatively favorable safety profile, and several AAV-based programs are already in clinical development for musculoskeletal conditions. The partial rather than complete rescue observed is typical of complex degenerative diseases, where multiple parallel pathological processes operate simultaneously.

Transcriptome profiling of MYDGF-deficient chondrocytes revealed a coherent shift in cell state: pathways responsible for building and maintaining the extracellular matrix were downregulated, while inflammatory signaling programs were upregulated. This molecular signature mirrors what is observed in aged and osteoarthritic cartilage, reinforcing the idea that loss of MYDGF pushes chondrocytes toward a senescence-like, catabolic phenotype. In effect, the study positions MYDGF as a key upstream factor that simultaneously supports telomerase activity and cartilage matrix remodeling, thereby connecting two previously separate strands of osteoarthritis research: the telomere-senescence literature and the matrix-homeostasis literature.

Several important questions remain open. The receptor through which MYDGF signals in chondrocytes has not been definitively identified, and mapping the downstream signaling cascade from receptor binding to TERT transcription will be essential for rational drug design. It is also unclear whether MYDGF acts directly on TERT gene regulation or indirectly through intermediate survival pathways such as Akt, which has been linked to TERT phosphorylation and activation in other cell types. The dose, timing, and duration of MYDGF expression that maximize cartilage protection while minimizing any proliferative risk will need careful definition, particularly given the well-documented association between telomerase reactivation and malignancy. Long-term safety studies in larger animal models, ideally with spontaneous rather than surgically induced osteoarthritis, would help address these concerns.

Translation from mouse models to human patients faces additional hurdles. Human articular cartilage is thinner and less regenerative than rodent cartilage, and human osteoarthritis typically develops over decades of cumulative mechanical loading, inflammation, and metabolic stress rather than within weeks of surgical destabilization. Patient populations are heterogeneous, with age-related, post-traumatic, and obesity-associated disease subtypes that may differ in their underlying biology. It is plausible that MYDGF supplementation would benefit the subset of patients whose disease is driven by chondrocyte senescence, and biomarkers of telomere dysfunction or senescence could eventually help identify responders. The detection of MYDGF expression in human synovial tissue suggests that an endogenous joint-protective axis already exists, raising the possibility that therapies could amplify this axis rather than introduce a foreign factor.

The broader significance of this work lies in its contribution to the growing recognition that aging mechanisms are actionable therapeutic targets. Telomere attrition is one of the recognized hallmarks of aging, and interventions that preserve telomere integrity in specific tissues, from hematopoietic stem cells to cartilage, are being explored across regenerative medicine. By identifying a secreted protein that naturally regulates telomerase in a tissue-relevant context, the study offers a conceptual framework for tissue-selective telomerase modulation. If subsequent research confirms the safety and efficacy of MYDGF-based approaches in larger models and ultimately in clinical trials, this line of investigation could transform osteoarthritis from a managed symptom into a modifiable disease process, while also informing therapeutic strategies for other age-related degenerative conditions in which chondrocyte or stromal cell senescence plays a central role.

Subject of Research: MYDGF as a telomerase activator and therapeutic target for osteoarthritis

Article Title: MYDGF as a telomerase activator and therapeutic target for osteoarthritis

Article References: MYDGF as a telomerase activator and therapeutic target for osteoarthritis. (n.d.). https://doi.org/10.1007/s44307-026-00119-6

Image Credits: AI Generated

DOI: 10.1007/s44307-026-00119-6

Keywords: MYDGF, telomerase, activator, therapeutic, target, osteoarthritis, scientific research